The estimated Net Worth of Christine Gebski is at least $6.82 Million dollars as of 10 November 2023. Ms Gebski owns over 3,788 units of Repligen stock worth over $4,128,056 and over the last 4 years she sold RGEN stock worth over $2,688,956.
Ms has made over 5 trades of the Repligen stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 3,788 units of RGEN stock worth $557,328 on 10 November 2023.
The largest trade she's ever made was selling 3,788 units of Repligen stock on 10 November 2023 worth over $557,328. On average, Ms trades about 727 units every 57 days since 2021. As of 10 November 2023 she still owns at least 28,787 units of Repligen stock.
You can see the complete history of Ms Gebski stock trades at the bottom of the page.
Christine Gebski is the Sr. VP of Filtration & Chromatography at Repligen.
Christine's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM, MA, 02453.
Over the last 21 years, insiders at Repligen have traded over $118,224,292 worth of Repligen stock and bought 160,440 units worth $1,459,521 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Glenn P Muir, and Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of $3,015,702. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth $1,139,034.
repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.
Repligen executives and other stock owners filed with the SEC include: